Matches in Wikidata for { <http://www.wikidata.org/entity/Q91606085> ?p ?o ?g. }
- Q91606085 description "2020 nî lūn-bûn" @default.
- Q91606085 description "2020年の論文" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年学术文章" @default.
- Q91606085 description "2020年學術文章" @default.
- Q91606085 description "2020年學術文章" @default.
- Q91606085 description "2020年學術文章" @default.
- Q91606085 description "2020年學術文章" @default.
- Q91606085 description "2020年學術文章" @default.
- Q91606085 description "2020년 논문" @default.
- Q91606085 description "article científic" @default.
- Q91606085 description "article scientific" @default.
- Q91606085 description "article scientifique" @default.
- Q91606085 description "articol științific" @default.
- Q91606085 description "articolo scientifico" @default.
- Q91606085 description "artigo científico" @default.
- Q91606085 description "artigo científico" @default.
- Q91606085 description "artigo científico" @default.
- Q91606085 description "artikel ilmiah" @default.
- Q91606085 description "artikull shkencor" @default.
- Q91606085 description "artikulong pang-agham" @default.
- Q91606085 description "artykuł naukowy" @default.
- Q91606085 description "artículo científico publicado en 2020" @default.
- Q91606085 description "artículu científicu" @default.
- Q91606085 description "bilimsel makale" @default.
- Q91606085 description "bài báo khoa học" @default.
- Q91606085 description "naučni članak" @default.
- Q91606085 description "scienca artikolo" @default.
- Q91606085 description "scientific article published on 06 April 2020" @default.
- Q91606085 description "scientific article published on 6 April 2020" @default.
- Q91606085 description "scientific article published on 6 April 2020" @default.
- Q91606085 description "teaduslik artikkel" @default.
- Q91606085 description "tieteellinen artikkeli" @default.
- Q91606085 description "tudományos cikk" @default.
- Q91606085 description "vedecký článok" @default.
- Q91606085 description "vetenskaplig artikel" @default.
- Q91606085 description "videnskabelig artikel udgivet 6. april 2020" @default.
- Q91606085 description "vitenskapelig artikkel" @default.
- Q91606085 description "vitskapeleg artikkel" @default.
- Q91606085 description "vědecký článek" @default.
- Q91606085 description "wetenschappelijk artikel" @default.
- Q91606085 description "wissenschaftlicher Artikel" @default.
- Q91606085 description "επιστημονικό άρθρο" @default.
- Q91606085 description "мақолаи илмӣ" @default.
- Q91606085 description "наукова стаття, опублікована у квітні 2020" @default.
- Q91606085 description "научна статия" @default.
- Q91606085 description "научная статья" @default.
- Q91606085 description "научни чланак" @default.
- Q91606085 description "научни чланак" @default.
- Q91606085 description "מאמר מדעי" @default.
- Q91606085 description "مقالة علمية نشرت في 6 أبريل 2020" @default.
- Q91606085 description "৬ এপ্রিল ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q91606085 description "บทความทางวิทยาศาสตร์" @default.
- Q91606085 description "სამეცნიერო სტატია" @default.
- Q91606085 name "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 name "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 type Item @default.
- Q91606085 label "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 label "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 prefLabel "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 prefLabel "Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-posit" @default.
- Q91606085 P1433 Q91606085-6ADB111B-927E-4630-9428-02F27019666B @default.
- Q91606085 P1476 Q91606085-E047A263-70E1-47BA-AD10-0E89325CCE1F @default.
- Q91606085 P2093 Q91606085-0D3FA8C9-9BB7-4D19-9557-6A5D6D96874F @default.
- Q91606085 P2093 Q91606085-1275AA1A-0EF5-41D8-992D-023E1BC04CC4 @default.
- Q91606085 P2093 Q91606085-1A382C60-A977-4C1C-AA1C-693F9BFC844A @default.
- Q91606085 P2093 Q91606085-1BC51CA8-E0E4-4351-B223-6C85801E009E @default.
- Q91606085 P2093 Q91606085-25B07EEF-A4E7-4C7F-9D24-F3FDD1057A03 @default.
- Q91606085 P2093 Q91606085-2A80CE39-A9D5-4527-83EA-985175CFA102 @default.
- Q91606085 P2093 Q91606085-544C193F-95F4-4609-8AB9-9249B545BCF0 @default.
- Q91606085 P2093 Q91606085-55D5DD46-8486-4C77-909A-9921529867E4 @default.
- Q91606085 P2093 Q91606085-91EA3B9B-4AB4-42BC-963B-231F81007D70 @default.
- Q91606085 P2093 Q91606085-B3AB8298-7563-4B66-B0EE-F419EB67F257 @default.
- Q91606085 P2093 Q91606085-C3378858-68FF-4F69-9C20-CEBA33439893 @default.
- Q91606085 P2093 Q91606085-D72D72A3-0496-44DB-ADD0-A5E401B1BD46 @default.
- Q91606085 P2093 Q91606085-DD83DB58-53CB-48D9-8DF2-05744AA5F144 @default.
- Q91606085 P2860 Q91606085-09754C93-645C-4093-B336-85293810D3BD @default.
- Q91606085 P2860 Q91606085-27101A8A-CDED-45A2-B279-5DDD3CB833F4 @default.
- Q91606085 P2860 Q91606085-294AF627-C67E-4BE1-91AF-5038F2DB8D85 @default.
- Q91606085 P2860 Q91606085-3BFDA83A-452D-4231-B93B-B95D9DF2EC2B @default.
- Q91606085 P2860 Q91606085-47146809-4CFA-47A4-B6F5-EE5ACE8A73FB @default.
- Q91606085 P2860 Q91606085-7DEDD371-C241-4BA7-A8FF-3322A7F63583 @default.
- Q91606085 P2860 Q91606085-8D840FEA-305D-4880-9699-AE6A92D512FD @default.
- Q91606085 P2860 Q91606085-97E0AD79-1826-4C9A-BDD9-249B26A663B0 @default.
- Q91606085 P2860 Q91606085-9A413D42-1010-4093-95AD-84A0CB539FE3 @default.
- Q91606085 P2860 Q91606085-A5E5C017-E2E9-4007-8ADB-36BB6913CA44 @default.
- Q91606085 P2860 Q91606085-B6F186EF-C65F-4512-B742-1A2EA8015843 @default.
- Q91606085 P2860 Q91606085-BE1903C9-EB2C-40C7-9BD1-C5B54C37EF07 @default.
- Q91606085 P2860 Q91606085-CC833BF6-B53C-440C-84D5-980888141A81 @default.
- Q91606085 P2860 Q91606085-D7D67ED6-CFE3-48F4-AD96-F9B44E18EF66 @default.
- Q91606085 P2860 Q91606085-DF5DE0A4-EC1F-4AFD-9A9B-B21F3A33F43B @default.
- Q91606085 P2860 Q91606085-E696FD56-8562-4E5A-8505-785F6F10A397 @default.
- Q91606085 P2860 Q91606085-E7E24AEF-2DF4-4184-B8F4-7B49D36950BE @default.
- Q91606085 P2860 Q91606085-F4DFA7E9-4A58-48F8-A97A-C36DD819E836 @default.
- Q91606085 P304 Q91606085-81C736D1-F782-447F-8C03-943C30BE9D9A @default.
- Q91606085 P31 Q91606085-84ACD7CC-CA3B-4C18-9A55-F653F7CF5D15 @default.